Urinary and plasma metabolite differences detected by HPLC-ESI-QTOF-MS in systemic sclerosis patients. Fernández Ochoa, Álvaro Quirantes-Piné, Rosa Borras Linares, María Isabel Gemperline, David PRECISESADS Clinical Consortium Alarcón Riquelme, Marta Eugenia Beretta, Lorenzo Segura Carretero, Antonio Metabolomics HPLC-ESI-QTOF-MS Systemic Sclerosis biomarker acylcarnitines 2-arachidonoylglycerol The work described has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement No. 115565, the resources for which are composed of a financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) companies’ in-kind contribution. The author IBL gratefully acknowledges the Spanish Ministry of Economy and Competitiveness (MINECO) in association with the European Social Fund (FSE) for the contract PTQ-13-06429, the author AFO received support from the Spanish Ministry of Education, Culture and Sports (FPU grant 14/03992). Systemic Sclerosis (SSc) is a chronic autoimmune disease whose origin and pathogenesis are not yet well known. Recent studies are allowing a better definition of the disease. However, few studies have been performed based on metabolomics. In this way, this study aims to find altered metabolites in SSc patients in order to improve their diagnosis, prognosis and treatment. For that, 59 SSc patients and 28 healthy volunteers participated in this study. Urine and plasma samples were analyzed by a fingerprinting metabolomic approach based on HPLC-ESI-QTOF-MS. We observed larger differences in urine than plasma metabolites. The main deregulated metabolic families in urine were acylcarnitines, acylglycines and metabolites derived from amino acids, specifically from proline, histidine and glutamine. These results indicate perturbations in fatty acid beta oxidation and amino acid pathways in scleroderma patients. On the other hand, the main plasma biomarker candidate was 2-arachidonoylglycerol, which is involved in the endocannabinoid system with potential implications in the induction and propagation of systemic sclerosis and autoimmunity. 2025-03-19T12:57:09Z 2025-03-19T12:57:09Z 2018-09-11 journal article Published version: Fernández Ochoa, Álvaro et al. Journal of Pharmaceutical and Biomedical Analysis Volume 162, 5 January 2019, Pages 82-90. https://doi.org/10.1016/j.jpba.2018.09.021 https://hdl.handle.net/10481/103191 10.1016/j.jpba.2018.09.021 eng info:eu-repo/grantAgreement/EC/FP7/115565 http://creativecommons.org/licenses/by-nc-nd/4.0/ open access Attribution-NonCommercial-NoDerivatives 4.0 Internacional Elsevier